Rain Therapeutics (NASDAQ:RAIN) reported quarterly losses of $(0.68) per share which met the analyst consensus estimate. This is a 2.86 percent increase over losses of $(0.70) per share from the same period last year.
$1000 Invested In This Stock 5 Years Ago Would Be Worth $4,000 Today
West Pharmaceutical Servs (NYSE:WST) has outperformed the market over the past 5 years by 23.61% on an annualized…